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Abstract
Recent outbreaks of Chikungunya virus (CHIKV) infection have been characterized by an increasing number of severe cases
with atypical manifestations including neurological complications. In parallel, the risk map of CHIKV outbreaks has
expanded because of improved vector competence. These features make CHIKV infection a major public health concern
that requires a better understanding of the underlying physiopathological processes for the development of antiviral
strategies to protect individuals from severe disease. To decipher the mechanisms of CHIKV infection in the nervous system,
a kinetic analysis on the host proteome modifications in the brain of CHIKV-infected mice sampled before and after the
onset of clinical symptoms was performed. The combination of 2D-DIGE and iTRAQ proteomic approaches, followed by
mass spectrometry protein identification revealed 177 significantly differentially expressed proteins. This kinetic analysis
revealed a dramatic down-regulation of proteins before the appearance of the clinical symptoms followed by the increased
expression of most of these proteins in the acute symptomatic phase. Bioinformatic analyses of the protein datasets
enabled the identification of the major biological processes that were altered during the time course of CHIKV infection,
such as integrin signaling and cytoskeleton dynamics, endosome machinery and receptor recycling related to virus
transport and synapse function, regulation of gene expression, and the ubiquitin-proteasome pathway. These results reveal
the putative mechanisms associated with severe CHIKV infection-mediated neurological disease and highlight the potential
markers or targets that can be used to develop diagnostic and/or antiviral tools.
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Introduction
Chikungunya virus (CHIKV), an Alphavirus belonging to the
Togaviridae family, is an arthropod-borne virus transmitted to
humans by Aedes spp. mosquitoes [1]. Since 2004, major epidemics
of Chikungunya fever have occurred in Africa and spread rapidly
to India and islands in the southwestern Indian Ocean, notably in
La Re´union between 2005 and 2006, when more than one third of
the population was affected with the infection, causing 203 deaths
[2]. Although Ae. aegypti is the classical vector of CHIKV, an
adaptive mutation of the virus to Ae. Albopictus during the La
Re´union outbreak increased the viral transmissibility and dissem-
ination [3]. Climate changes and increased international exchang-
es of products and people have favored the dissemination of Ae.
albopictus that colonized the temperate regions of Europe and the
Americas [4,5]. Therefore, the wide distribution of Ae. albopictus
and its establishment in temperate regions have modified the risk
map of CHIKV outbreaks [6]. A recent CHIKV epidemic in
northeastern Italy highlighted the increased risk of the emergence
of arboviruses transmitted by local competent mosquitoes in
Europe [7,8]. These outbreaks were directly linked to the return of
tourists from India and the affected islands in the Indian Ocean.
The risk of CHIKV transmission arises from the simultaneous
presence of the virus, well-adapted vectors and susceptible human
hosts. The spread of the Chikungunya epidemic has caused
significant social and economic losses (high economic cost and
human suffering) [9]. CHIKV is now considered a global health
concern. In the absence of a vaccine or specific treatment, the
primary mechanism to protect individuals from CHIKV infection
is the prevention of bites from infected Aedes spp. using a
combination of personal protective measures and vector control
strategies [10]. However, protection cannot be restricted to anti-
vector measures. Antiviral strategies against CHIKV infection
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must be developed for the prevention and/or treatment of the
clinical manifestations associated with this arboviral disease.
The symptomatology of CHIKV infection was first described in
the mid-1950s after an outbreak of Dengue disease in Tanzania in
1952 [11,12]. Although five percent of the infected people are
asymptomatic, the disease is mainly characterized by fever, rash,
headache and incapacitating joint pain (arthralgia) [13]. Chikun-
gunya fever is rarely fatal, and most symptoms are resolved within
a few weeks; nevertheless, some patients have persistent joint pain
in the form of recurrent or persistent episodes that last for months
to years [14]. Whereas the neurological complications were
described in the 1960s [15,16], the severe clinical forms involving
the central nervous system (CNS) were not uncommon during the
Chikungunya outbreak that occurred in La Re´union from March
2005 to April 2006 [17]. This outbreak was characterized by a
large number of atypical manifestations, including neurological
disorders, which are listed as a major cause of death among
individuals with severe CHIKV infection [18]. The increased
susceptibility of newborns and the elderly to neurological
complications supported the age-dependent association of these
severe forms [19]. Additionally, the first mouse model of CHIKV
infection developed by Couderc and collaborators [20] revealed
the dissemination of the virus to the choroids plexuses and
leptomeninges in the CNS in severe infections. This animal model
has improved knowledge about the pathogenicity and cell/tissue
tropisms of the virus, confirming that CHIKV can disseminate in
the CNS.
To prevent and/or treat severe neurological disease in humans,
a better understanding of the neurological consequences of
CHIKV infection before and after the appearance of neurological
clinical symptoms is needed. To elucidate the pathogenesis of
CHIKV infection and identify the host factors hijacked by
CHIKV to complete its viral replication cycle, the protein profile
changes following CHIKV infection in vitro and in vivo were
analyzed using state-of-the art technology. The in vitro experiments
using CHIKV-infected hepatic or microglial cell lines collected
before cell death revealed the down-regulation of host proteins
involved in diverse cellular pathways and biological functions,
including transcription, translation, cell signaling and lipid and
protein metabolism [21,22]. The in vivo experiments comparing
the liver and brain protein expression patterns in mock- and
CHIKV-infected mouse tissues collected at the peak symptomatic
phase showed an alteration of the proteins involved in stress
responses, inflammation, metabolism and apoptosis [23]. In
contrast to the in vitro experiments, most of the differentially
expressed proteins in the infected mouse brain tissue were up-
regulated. The differences between the global protein expression
patterns could be attributed, in part, to the different time points
chosen in each proteomics analysis. The in vitro experiments
focused on early proteome alterations following CHIKV infection,
whereas the in vivo experiments investigated the molecular
consequences of viral infection after the appearance of clinical
symptoms.
Therefore, to obtain a comprehensive view of the pathophys-
iological processes associated with the clinical onset of neurological
CHIKV infection, a kinetic analysis was performed on the protein
expression profiles in the brain of CHIKV-infected mice collected
before and after the onset of clinical symptoms. The host proteome
modifications were determined using two proteomic approaches
(2D-DIGE and iTRAQ) followed by protein identification by mass
spectrometry (MS). Ingenuity Pathway Analysis (IPA) of the total
dataset of proteins that were differentially expressed at the early
and late time-points enabled the determination of the main
networks and pathways modified during CHIKV infection in the
brain. Detailed analysis of the proteins involved in these networks
and pathways provided insight into the protein interactions and
biological processes that are involved in the pathogenesis of the
neurological disease caused by CHIKV infection. This study also
highlighted the biomarkers of severe atypical symptoms and
potential targets for antiviral research.
Materials and Methods
Ethics statement
All animal experiments described in this paper have been
conducted according to Dutch guidelines for animal experimen-
tation and approved by the Animal Welfare Committee of the
Erasmus Medical Centre, Rotterdam, the Netherlands. All efforts
were made to minimize animal suffering.
Reagents
N-hydroxy succinimide ester Cy2, Cy3 and Cy5, urea, glycerol,
mineral oil, immobiline DryStrip gels (18 cm, pH = 3–10, pH = 4–
7 and pH = 6–11) and IPG buffer solutions (pH = 3–10, 4–7 and
6–11) were purchased from GE Healthcare (Piscataway, NJ).
Acrylamide, DTT, Tris, glycine and SDS were purchased from
Bio-Rad (Hercules, CA, USA). Dimethyl formamide (DMF),
CHAPS, L-lysine, ammonium persulfate, iodoacetamide, agarose,
bromophenol blue and TFA were purchased from Aldrich (Poole,
Dorset, UK). Thiourea, TEMED, acetone, acetonitrile (ACN) and
ethanol were purchased from Fluka (Buchs, Switzerland). Trypsin
(sequencing grade) was purchased from Promega (Madison, WI).
All buffers were prepared with Milli-Q water (Millipore, Belford,
MA, USA). Imperial Protein Stain solution was purchased from
Thermo Scientific (Rockford, IL, USA).
Mouse infection
Nine-day-old female C57/Bl6 mice were infected intra-perito-
neally (i.p) with 105 TCID50 per mouse of CHIKV strain S27 in
100 ml volumes. Mock infected mice (n = 6) received the same
volume of medium and were sacrificed on day 2 post infection.
CHIKV-infected mice were sacrificed on the first day that virus
was present in the brain (Day 2 post infection; n = 6) and on the
first day of neurological symptoms (Day 3 post infection). Two
different disease manifestations were observed on day 3 post
infection: mice exhibited paralysis-like symptoms (n = 6) or
tetanus-like symptoms (n = 6). Brains were collected immediately
after humane euthanasia by cervical dislocation under isoflurane
anesthesia and cerebellum was separated to reduce protein
background. Brains were cut in half and the left hemisphere of
each mouse was washed rapidly in ice-cold PBS to remove residual
blood contaminants. Brains were then snap-frozen and stored in
280uC until processing. Mice were maintained in isolator cages
throughout the infection experiment, had a 12-hour day-night
cycle and were fed ad libitum. Animal experiments were approved
by the Animal Ethics Committee of Erasmus Medical Center.
Virus presence in the brain was confirmed by means of detection
of viral RNA and antigen in brains samples from all mice. Viral
RNA was extracted from brain samples using the automated
MagnaPure method (Total nucleic acid isolation kit, Roche
Diagnostics, the Netherlands) according to the manufacturer’s
instructions, and detected using a one-step RT-PCR TaqMan
protocol (EZ-kit, Applied Biosystems) in an ABI PRISM 7500
detection instrument. The primers and probe used for CHIKV
RNA detection were: CHIKV-reverse CCAAATTGTCC
GGGTCCTCCT; CHIKV-forward AAGCTCCGCGTCCTT-
TACCAAG and probe Fam-CCAATGTCTTCAGCCTGGA-
CACCTTT-Tamra [24,25].
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Viral antigen was detected in formalin fixed, paraffin embedded
tissues as follows: 4-mm thick paraffin sections were deparaffinized
in xylene, rehydrated in descending concentrations of ethanol and
incubated for 10 min in 3% H2O2 diluted in PBS to block
endogenous peroxidase activity. Antigen retrieval was performed
by incubation for 15 min at 121uC in citrate buffer (0.01 M,
pH 6.0). Sections were incubated overnight at 4uC with rabbit-
anti-CHIKV capsid (1:5000), antibody followed by secondary goat
anti-rabbit IgG-PO antibody (1:100; Dako, The Netherlands).
Sections were counterstained with Mayer’s hematoxylin and
mounted with Kaiser’s glycerin-gelatin and analyzed using a light
microscope.
Protein sample preparation
Half brain hemispheres from non-infected mice and mice
infected with CHIKV were collected before and after the
appearance of clinical signs corresponding to early and late
time-points, respectively. CHIKV-infected mice were separated
into three groups: early (n = 6, CH-E1 to E6) sampled at day
two and two late groups showing two different symptoms (see
above ‘‘mouse infection’’ section for details); late ‘‘paralytic’’
(n = 6, CH-LP1 to LP6) and late ‘‘tetanus-like’’ (n = 6, CH-LT1
to LT6) sampled at day three. Control group (mock, n = 6, C1 to
C6) was sampled at day two. Brain samples were stored at
280uC and further processed in biosafety level 3 laboratory
(Dept. of Virology, IRBA Marseille) until complete homogeni-
zation. Briefly, each brain sample was lysed with 1 ml of lysis
buffer containing 2% SDS, 125 mM Tris-HCl pH = 6.8, 10%
glycerol and 5% mercaptoethanol, and homogenised by
mechanical disruption using metal beads and the Tissue Lyser
apparatus (QIAGEN). The resulting homogenates were centri-
fuged for 15 min at 16 000 x g at 4uC and the supernatant was
collected and stored at 280uC. The protein concentration of
each sample was determined by the Lowry method (DC
Protein assay Kit, Bio-Rad) according to the manufacturer’s
instructions.
CyDye labeling
Samples were subjected to 2-D clean-up kit (GE healthcare) and
the protein pellet was resuspended in standard cell lysis buffer
containing 8 M urea, 2 M thiourea, 4% (w/v) CHAPS and
30 mM Tris, adjusted to pH 8.5 (UTC buffer) at a protein
concentration of 2.5 mg/mL. Sample quality and protein amount
was checked out by loading 10 mg of each sample onto a 10%
SDS-PAGE precast gel (BioRad) stained with Imperial Protein
Stain solution (Fisher Scientific) (data not shown). Proteins in each
sample were minimally labeled with CyDye according to the
manufacturer’s recommended protocols and as previously de-
scribed [26] [27]. An internal standard pool was generated by
combining an equal amount of each sample included in the study
and was labeled with Cy-2. Cy3-, Cy5- and Cy2-labeled samples
were then pooled (Supplementary Tables S1 and S2), and an equal
volume of UTC buffer containing 10 mM DTT and 1% (v/v)
immobilized pH gradient (IPG) buffer corresponding to the IPG
strips used, was added.
Two-dimensional electrophoresis
Labelled-samples were first separated by isoelectric focusing
(IEF) with precast 18-cm IPG strips with different pH gradient
ranges (3–10 L, 4–7 or 6–11), followed by a second dimension
separation on 10% SDS-PAGE, as previously described [27].
Image analysis
After electrophoresis, the gels with Cydye-labeled proteins were
scanned with a Typhoon Trio Image scanner (GE Healthcare
UK). Prescans were performed to adjust the photomultiplier tube
(PMT) voltage to obtain images with a maximum intensity of 60
000 to 80 000 U. Images were cropped with ImageQuant software
(GE Healthcare UK) and further analyzed using the software
package Progenesis SameSpot v2 software (Nonlinear Dynamics,
Newcastle upon Tyne, UK). Background subtraction and spot
intensity normalization were automatically performed by Progen-
esis SameSpots. Protein spots which presented a significant
abundance variation between the 3 experimental groups
(|ratio|$1.3, ANOVA p#0.05) were marked and submitted to
MS for identification.
In-gel Digestion
Based on the Progenesis SameSpot analysis, protein spots of
interest from gels stained with ImperialTM Protein Stain solution
were excised and digested using a Shimadzu Xcise automated gel
processing platform (Shimadzu Biotech, Kyoto, Japan) as
described previously [28] and stored at 220uC until their analysis
by MS
Mass spectrometry analysis of peptide mixture from gel
elution and data analysis
The samples were subjected to nanoscale capillary liquid
chromatography-tandem mass spectrometry (nano LC-MS/MS)
analysis with a QTOF apparatus (Q-TOF Ultima, Waters, MA) as
previously described [26]. The peak lists generated in the
micromass pkl format, were then fed into a local search engine
Mascot Daemon v2.2.2 (Matrix Science, London, UK) against a
mixed Mus musculus and Chikungunya virus homemade protein
database (SwissProt). Search parameters were set in order to allow
one missed tryptic cleavage site, the carbamidomethylation of
cysteine, and the possible oxidation of methionine; precursor and
product ion mass error tolerance was ,0.2 Da. All identified
proteins have a Mascot score greater than 35 (Mixed: Mus musculus,
Chikungunya virus, 16487 sequences extracted from Swis-
sprot_2012_02), corresponding to a statistically significant
(p,0.05) confident identification.
iTRAQ labeling
For iTRAQ labeling, a sample pool of each experimental group
was generated by mixing an equal amount of each sample per
group (mock, pool-C; early, pool-E; and late, pool-LP and pool-
LT). Six mice per group were pooled. Each pool was then divided
into two replicates (mock, pool-C1-C2; early pool-E1-E2 and late
pools-LP1-LP2 and LT1-LT2) containing 100 mg of protein.
Proteins were precipitated with cold acetone for 2 h at – 20uC,
centrifuged for 15 min at 16 000 6 g, dissolved in 20 mL of
Dissolution buffer, denatured, reduced, alkylated and digested
with 10 mg of trypsin overnight at 37uC, following manufacturer’s
protocol (iTRAQ Reagent Multiplex Buffer kit, Applied Biosys-
tems, Foster City, CA, USA) and as previously described [29]. The
resulting peptides were labeled with iTRAQ reagents (iTRAQ
Reagent-8Plex multiplex kit, Applied Biosystems) according to
manufacturer’s instructions and as presented in the Supplemen-
tary Table S3. Before combining the samples, a pre-mix
containing an aliquot of each sample, cleaned-up using a ZipTip
was analysed by MS/MS to check out peptide labeling efficiency
with iTRAQ reagents and homogeneity of labeling between each
sample. The content of each iTRAQ reagent-labeled sample was
pooled into one tube according to this previous test. The mixture
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was then cleaned-up using an exchange chromatography (SCX/
ICAT cation exchange cartridge, ABsciex, Foster City, USA) and
reverse-phase chromatography C18 cartridge (C18 SpinTips,
Proteabio, Nıˆmes, France), prior to be separated using off-gel
system (Agilent 3100 OFFGEL fractionator, Agilent Technolo-
gies), as previously described [27].
Mass spectrometry analysis of peptide fractions from
off-gel separation
For nanoLC MS measurements, approximately 5 mg of peptide
sample was injected onto a nanoliquid chromatography system
(UltiMate 3000 Rapid Separation LC (RSLC) systems, Dionex,
Sunnyvale, CA). After pre-concentration and washing of the
sample on a Dionex Acclaim PepMap 100 C18 column
(2 cm6100 mm i.d. 100 A, 5 mm particle size), peptides were
separated on a Dionex Acclaim PepMap RSLC C18 column
(15 cm675 mm i.d., 100 A, 2 mm particle size) (Dionex,
Amsterdam) using a linear 90 min gradient (4–40% acetonitrile/
H20; 0.1% formic acid) at a flow rate of 300 nL/min. The
separation of the peptides was monitored by a UV detector
(absorption at 214 nm). The nanoLC was coupled to a nanospray
source of a linear ion trap Orbitrap MS (LTQ Orbitrap Velos,
Thermo Electron, Bremen, Germany). The LTQ spray voltage
was 1.4 kV and the capillary temperature was set at 275uC. All
samples were measured in a data dependent acquisition mode.
Each run was preceded by a blank MS run in order to monitor
system background. The peptide masses were measured in a
survey full scan (scan range 300–1700 m/z, with 30 K FWHM
resolution at m/z = 400, target AGC value of 106 and maximum
injection time of 500 ms). In parallel to the high-resolution full
scan in the Orbitrap, the data-dependent CID scans of the 10 most
intense precursor ions were fragmented and measured in the linear
ion trap (normalized collision energy of 35%, activation time of
10 ms target AGC value of 104, maximum injection time 100 ms,
isolation window 2 Da and wideband activation enabled). The
fragment ion masses were measured in the linear ion trap to have a
maximum sensitivity and the maximum amount of MS/MS data.
Dynamic exclusion was implemented with a repeat count of 1 and
exclusion duration of 37 sec.
Data analysis
Raw files generated from MS analysis were combined and
processed with Proteome Discoverer 1.1 (Thermo Fisher Scien-
tific). This software was used for extraction of MGF files. Protein
identification and quantification were carried out using ProteinPi-
lot version 4.0 (Applied Biosytems). The search was performed
against the mixed database containing 55536 sequences (54080
sequences from Mus musculus (extracted from Uniprot the 13th
December 2011) + 1300 sequences from Chikungunya virus, and
156 classical contaminant proteins). Data were processed as
described previously [30].
SDS-PAGE, Blotting, and Analysis Procedures
Immunoblotting with fluorescence-based methods was used to
detect both the total protein expression profile and the specific
immunoreactive proteins, as described previously [26]. The same
protein samples used for proteomic analysis were minimally
labeled with CyDye (i.e., Cy3) as described above (see ‘‘CyDye
Labeling’’ section). Labeled samples were separated by 10% or 4–
20% SDS-PAGE in a Mini-PROTEAN Cell (Bio-Rad) according
to the molecular weight of the targeted proteins. Gels were
transferred to a nitrocellulose membrane (0.2 mm; GE Healthcare)
using a semidry blotting system at 200 mA for 30 min (TE 77
PWR Semi-Dry Transfer Unit, GE Healthcare) [31]. Blots were
saturated with 5% nonfat dried milk in PBS containing 0.05%
(v/v) Tween 20 (PBS-T-milk) for 1 h. Western blot (WB) analyses
were carried out with rabbit mono- or polyclonal antibodies
directed against b-arrestin (1:5000, ARRB1, no. 4674, Cell
Signaling Technology, Danvers, MA), GRIP-associated protein
(1:500, GRASP1, no. sc-135681, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), annexin A2 (1:100, ANXA2, no. sc-9061, Santa
Cruz), integrin aV (1:100, ITGAV, no. 10179, Santa Cruz),
myosin phosphatase target subunit 1 (1:100, MYPT1, no. sc-
25618, Santa Cruz), rabaptin-5 (1:1000, RABEP1, no. sc-15351,
Santa Cruz), N-Ras (1:500, N-Ras, no. sc-519, Santa Cruz),
synaptogyrin-3 (1:1000, SYNGR3, no. sc-68936, Santa Cruz), or
with a goat polyclonal antibody directed against c-aminobutyric
acid receptor subunit alpha-1 (1:100, GABAARa1 or GABRA1,
no. sc-31045, Santa Cruz), diluted in PBS-T-milk and incubated
overnight at 4uC. After three washes in PBS-T, primary rabbit
antibodies were revealed with ECL Plex goat anti-rabbit IgG Cy5-
conjugated secondary antibody (1:1000, GE Healthcare), and
rabbit anti-goat IgG fluorescein isothiocyanate (FITC) conjugate
(1:400, Southern Biotech, Birmingham, AL) was used for the
detection of anti-GABAARa1 goat antibody diluted in PBS-T-
milk. All manipulations were protected from light. The gels
electrophoresis and immunoblots were scanned using a Typhoon
Trio image scanner as mentioned above (see ‘‘Image Analysis’’
section). Immunoreactive bands were analyzed using TotalLab
Quant v12.2 software (Nonlinear Dynamics). To evaluate the
expression level of the different proteins, immunoreactive band
intensities were normalized to the intensities of a global protein
pattern labeled with Cy3 as described previously [26]. Band
intensities were also corrected for the adjacent background.
Differences in the relative abundance of each protein between
two independent groups were determined using Student’s t-test.
All differences were considered significant at p ,0.05 and
statistical analysis was performed using GraphPad Prism v5.01
statistical software (GraphPad Software Inc., La Jolla, CA).
Standard molecular weight markers were loaded in each gel
(Bio-Rad).
Ingenuity pathway analysis
A dataset containing deregulated proteins obtained from 2D-
DIGE and iTRAQ analysis and their corresponding expression
values (fold-change and p-values) were uploaded into the IPA
software, Inc (http://www.ingenuity.com), taking into account to
protein expression evolution according to clinical onsets. Proteins
whose expression was significantly deregulated (|fold-change| $
1.3, p-value # 0.05), were selected for the analysis. The IPA
program uses a knowledgebase (IPA KB) derived from the
scientific literature to relate genes or proteins based on their
interactions and functions. Ingenuity Pathway Analysis generates
biological networks, canonical pathways and functions relevant to
the uploaded dataset. A right-tailed Fisher’s exact test is used for
calculating p-values to determine if the probability that the
association between the proteins in the dataset and the functional
and canonical pathway can be explained by chance alone. The
final scores are expressed as negative log of p-values and used for
ranking. The scores are derived from a p-value (score = 2log (p-
value)) and indicate the likelihood that focus proteins (i.e., the
identified proteins within a network)) are clustered together. Thus,
these proteins and their association with the IPA KB were used to
generate networks and to perform functional canonical pathway
analyses.
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Results
Virus Infection Conditions
The presence of the CHIKV RNA in the brains collected from
CHIKV-infected mice at the indicated time points was verified by
real-time RT-PCR using primers and probes targeting the capsid-
encoding region of the viral RNA. The viral RNA was detected on
days 2 and 3 post-infection. On day 3, 50- to 100-fold more viral
RNA was detected in the brains of infected animals. There was no
difference in the RNA level in animals with paralysis and tetanus-
like symptoms. Using immunohistochemistry, the viral antigen was
detected in the brain of infected animals with paralysis and
tetanus-like symptoms (Figure 1). The antigen was detected in the
cortex and thalamus of the brain collected at days two and three
post-infection. None of the mock-infected mice expressed the viral
RNA or antigen.
2D-DIGE analysis to detect the differentially expressed
proteins following CHIKV infection
Using the Progenesis SameSpot v.2 software, the abundance of
23 protein spots was found to be significantly different (ANOVA,
p-value # 0.05) among the four groups (M, E, LP and LT) with
fold changes $ 30% (|FC| $ 1.3, in the pH range 3–10;
Figure 2A). The majority of the protein spots were significantly
altered at the late time points in the infected mice relative to the
mock-infected mice (LP vs M, n = 15; eight up-regulated and seven
down-regulated, and LT vs M, n = 15, nine up-regulated and six
down-regulated, Figures 2C and 2D). Nine protein spots were
significantly different in the infected mice at the early time point
relative to the mock-infected group (five up-regulated and four
down-regulated, Figure 2B). Finally, seven and eight protein spots
were significantly different in the LP and LT samples, respectively,
relative to the early samples (LP vs E, three up-regulated and four
down-regulated; and LT vs E, three up-regulated and five down-
regulated, Figures 2E and 2F). Notably, among the modified
protein spots, few differences were observed between the LP and
LT samples relative to either the mock or early samples.
To better understand the early pathophysiological processes
following CHIKV infection and to improve the determination of
host proteome changes before the appearance of clinical signs, 2D-
DIGE analyses were performed on the mock-infected samples
relative to the infected samples at the early time point using
narrower pH range IPG strips (e.g., pH 4–7 and 6–11). Using the
pH 4–7 IPG strips for the IEF, nine protein spots were found to be
significantly different between the early and mock-infected samples
(|fold-change| $ 1.3, p # 0.05) (seven up-regulated and two
down-regulated, Figure S1). However, no protein spots were found
to be significantly different using the pH 6–11 IPG strips (data not
shown). Considering both pH ranges (i.e., pH 3–10 and 4–7), the
abundance of 18 protein spots was found to be significantly
modified at the early time point compared to the mock-infected
group. Overall, the DIGE analysis of the brain tissue following
CHIKV infection revealed that the abundance of 32 protein spots
was altered.
Identification of modified protein abundance following
CHIKV infection using 2D-DIGE analyses
Among the 23 protein spots detected using the pH 3–10 range
analysis, 18 (78.3%) were successfully identified with a high degree
of confidence; these spots corresponded to 16 distinct proteins
according to their accession numbers, including seven proteins
identified in the early samples (Table 1). These proteins were
grouped into functional categories according to their gene
ontology (GO). No viral protein was identified. Two spots
contained more than one identified protein (#469 and #628),
and three proteins could be identified in more than one spot
(DPYSL2, DPYSL3 and AL1L1). Five protein spots were not
identified, most likely because of insufficient amounts of proteins
or low MS spectra qualities.
The nine spots that the pH 4–7 range analysis revealed to be
differentially expressed in the infected samples at the early time
point were all identified; these spots corresponded to eight distinct
host proteins based on their SwissProt accession numbers
(Supplementary Table S4). The dynactin subunit 1 (DCTN1)
was identified in two spots. Similar to the pH 3–10 analysis, no
viral protein was identified. Notably, the early up-regulation of the
dihydropyrimidinase-related protein 2 (DPYSL2) was confirmed
using the pH 4–7 analysis. Therefore, the use of the narrower pH
range enabled the identification of seven proteins in addition to
those identified using the pH 3–10 range; therefore, 14 distinct
proteins were identified as differentially expressed before the
appearance of clinical signs. Considering the results obtained using
both pH ranges in the 2D-DIGE analyses and the different paired
comparisons, 22 unique host proteins were identified.
Identification of differentially expressed proteins
following CHIKV infection using iTRAQ-labeling
To further characterize the proteome changes in the mouse
brain after CHIKV infection, an off-gel quantitative proteomic
analysis was performed using the iTRAQ reagent, which allowed
Figure 1. Viral antigen in the brains of CHIKV infected mice. A: CHIKV-antigen present in the cortex of CHIKV-infected mice two days post
infection (objective 10x). B: CHIKV-antigen present in the thalamus of infected mice three days post infection (objective 10x).
doi:10.1371/journal.pone.0091397.g001
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the labeling and comparison of 8 different samples (Supplementary
Table S3). The data were analyzed with the Protein Pilot software
using the parameters described above. More than 3000 proteins
were initially identified; following the application of the local False
Discovery Rate (FDR) of 5% and the exclusion of contaminants,
2686 proteins identified and quantified, which were included in
the analysis.
A total of 178 distinct host proteins were found to be
significantly different (p # 0.05) among the four groups (M, E,
LP and LT) with a fold-change $ 30% (|FC| $ 1.3)
(Supplementary Table S5). Among these proteins, 129 were
differentially expressed in the CHIKV-E- and mock-infected mice,
with 87% of the proteins being down-regulated (17 up-regulated
and 112 down-regulated). In the CHIKV-LP- and early-infected
mice, 138 proteins were differentially expressed with 96% of the
proteins being up-regulated (133 up-regulated and five down-
regulated). In the CHIKV-LT and early-infected samples, 144
proteins were differentially expressed with more than 98% of the
proteins being up-regulated (142 up-regulated and two down-
regulated). Among the proteins differentially expressed at the late
time-point compared to control samples, 91 proteins were
significantly different in the CHIKV-LP- and mock-infected mice
(51 up-regulated and 40 down-regulated) and 85 proteins were
significantly different in the CHIKV-LT and mock-infected
samples (55 up-regulated and 30 down-regulated).
Combination of in-gel (2D-DIGE) and off-gel (iTRAQ-
labeling) analyses
Because the objective of this kinetic study was to determine the
protein profile alterations during the evolution of clinical signs,
only the proteins that were significantly differentially expressed in
the late (LT or LP) and early-infected samples, and in the early-
infected and mock samples were included in the combined analysis
of the DIGE and iTRAQ data. Considering the times at which the
two late symptoms occurred, analysis of the three comparisons (E
vs M, LP vs E and LT vs E) generated a total of 177 unique host
proteins that were differentially expressed in the brain tissue
samples after CHIKV infection at early and/or late time-points
(2D-DIGE, n = 17; iTRAQ, n = 161; CRMP1 was detected using
both methods). The subcellular distributions and the GO
functional classifications were determined for the proteins that
were significantly differentially expressed during CHIKV infec-
tion. The proteins were located mainly in the cytoplasm (.45%),
the membrane (22%) and the nucleus (20%) (Figure 3A). The
differentially expressed proteins were mainly involved in tran-
scription/translation (14%), nervous system development (12%),
cytoskeleton organization (11%), metabolism (11%) and transport
(10%); others were related to cell cycle, ubiquitination or apoptosis
(.5%) (Figure 3B). Among the 177 differentially regulated
proteins, the majority (n = 110, 62.1%) showed differential
expression in all three comparisons, and 36 proteins showed
differential expression in paired comparisons (Figure 3C). Finally,
a few proteins were found to be differentially expressed in only one
comparison (n = 31), particularly in the LP or LT groups
compared to the early time-point, corresponding to six and three
Figure 2. 2D-DIGE analysis (pH 3–10) of mock (M)-, early (E), late paralytic (LP) and late tetanus-like (LT) CHIKV-infected brain
samples. (A) Representative data from a 2D-DIGE experiment using a 10% SDS-polyacrylamide gel with the pH 3–10 range is shown. Proteins from
M-, E- and LP- and LT- CHIKV-infected brain samples were labeled with Cy5 or Cy3 cyanine dyes, as described in Table S1. As determined by
Progenesis SameSpot software, protein spots that were differentially regulated between the four experimental groups (|FC| $1.3 and p #0.05), were
submitted to mass spectrometry for identification. The numbers annotated on the gel corresponded to master gel numbers of deregulated protein
spots. Spots were all identified as Mus musculus proteins and were listed in Table 1. Spots differentially modified between E and mock- (B), LP- and E-
(C), LT and E- (D), LP and M- (E) and LT and M- (F) infected samples are represented by red (up-regulated) or blue (down-regulated) dots.
doi:10.1371/journal.pone.0091397.g002
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proteins, respectively. These results highlighted that the number of
proteins differentially expressed between the two late time-points
(LT and LP) is relatively low. The hierarchical cluster analysis
clearly indicated that at the early time-point, the large majority of
proteins were down-regulated (80%) and subsequently up-regu-
lated when both the late clinical symptoms occurred (.95%)
(Figure 3D).
Networks, biological pathways and functions involved in
the clinical evolution of CHIKV infection in the brain
The 177 unique host proteins whose levels were found to be
significantly altered based on the three comparisons (E vs M, LP vs
E and LT vs E) were uploaded into IPA to statistically determine
the functions and pathways most strongly associated with the
protein list and to establish interactions with other proteins in
known networks. Eleven relevant networks were generated by IPA
and the top 5 are listed in Table 2. Among these networks, the top
two had clearly higher scores ($ 37) and included more than 20
focus molecules involved in functions related to cell or tissue
morphology and infectious disease (network 1); and cell-to-cell
signaling and interaction, cellular assembly and organization, and
cellular compromise (network 2). These networks were overlaid
with the fold changes in protein expression determined in each
comparison (E vs M, LP vs E and LT vs E) to highlight the proteins
whose levels were altered during the time-course of the infection
and according to the late symptoms (Figure 4) [32]. Network 1
contained proteins involved in actin cytoskeleton organization
(Actin, Tubulin, Spectrin, CAPZ, and CORO2B), nervous system
and recycling machinery (DPYSL, GRIPAP1, and ARRB1) and
gene expression regulation (SRRM2, EIF3H, and EIF3K).
Network 2 contained proteins related to integrin signaling and
cytoskeleton dynamics (ITGAV, ITGB1, and LAMB1), endocy-
tosis and synapse plasticity (GABRA1, PICK1, RABEP1, and
NSF), and ubiquitination (RBX1, and RNF213).
Of the 208 canonical pathways identified, 26 presented a
significant association (-Log (p-value) .2.0, Supplementary Table
S6). The most relevant pathways were related to cell junctions and
integrin signaling or associated with endocytosis phenomena (i.e.,
clathrin-mediated endocytosis (CME) and virus entry via the
endocytic pathways) and nervous system signaling (i.e., CDK5,
semaphoring signaling in neurons, and neuregulin). In addition,
the biological functions associated with the protein dataset, ranked
by significance, corresponded to cellular assembly and organiza-
tion (p-value: 1.36E-05; n = 54), cellular function and maintenance
(p-value: 2.11E-05; n = 49) and the cell cycle (p-value: 4.40E-05;
n = 32). Furthermore, 53 molecules were associated with cell death
and survival (p-value: 1.80E-03). In terms of diseases and disorders,
48 proteins were significantly associated with neurological disease
(p-value: 5.20E-04), consistent with the observation that 27 of the
molecules were mostly significantly related to nervous system
development and function (p-value: 1.68E-04).
Verification of the differential expression of selected
candidate proteins
Among the 177 differentially expressed proteins identified, 9
candidates were selected because they were present in the top 2
networks and the most significant canonical pathways and/or
representative of integrin signaling and cytoskeleton dynamics
(integrin aV (ITGAV), myosin phosphatase target subunit 1
(MYPT1), NRAS), receptor recycling (arrestin-b1 (ARRB1),
GRIP-associated protein (GRIPAP1 or GRASP), annexin A2
(ANXA2), rabaptin-5 (RABEP1)) and synapse function (c-
aminobutyric acid receptor subunit alpha-1 (GABRA1), and
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synaptogyrin (SYNGR3)). For all WB, each protein sample was
labeled with the cyanine-3 dye to reveal any variations in sample
loading, which were considered for the normalization and the
calculation of the average band volume ratio that was detected by
each specific antibody and revealed by a fluorescence-conjugated
secondary antibody (FITC or ECL Plex system). Using these
conditions, the protein levels during the course of CHIKV
infection in the mouse brain were determined.
The significant relative down-regulation between the mock- and
early-infected samples and relative up-regulation between the
early and LP or LT time points that were detected using the
proteomic approaches were confirmed for RABEP1, SYNGR3,
GRASP1, ARRB1, GABRA1 and ANXA2 by WB (Figure 5).
However, the increased expression of GRASP1 in the LT samples
compared to the early-infection samples was not significant in the
WB analysis. Although the differential expression of ITGAV and
NRAS measured by WB was consistent with the proteomic results
according to clinical symptom onset, the protein variations
observed were only significantly different between LT or LP vs E
for ITGAV and between LT vs E for NRAS. The MYPT1
differential expression was not significant in the WB analysis,
irrespective of the pair-wise comparison performed.
Collectively, for the majority of the selected proteins, the
expression variations measured by WB analysis were consistent
with the DIGE and iTRAQ analyses over the time course of the
clinical symptoms. Nevertheless, the protein abundance changes
measured by WB were lower than those detected using the
proteomic approaches (Figure 5, Tables 1, S4 and S5). Several
previously described factors might affect this validation step [27].
Discussion
To allow therapeutic intervention of the pathophysiological
processes involved in the CHIKV neuro-invasive disease, knowl-
edge of the kinetics of the host protein expression profiles is crucial.
Therefore, mouse brain tissues were sampled before and after the
appearance of severe clinical symptoms following CHIKV
infection, and the protein expression profiles were monitored
using comprehensive quantitative proteomic approaches. Unex-
pectedly, two distinct clinical manifestations were observed in the
infected mice, one group showing paralytic symptoms (LP), and
the other presenting tetanus-like symptoms (LT). Considering
these two clinical signs and focusing the analysis on the alteration
of protein profiles, comparisons were limited to successive time
points (i.e., E vs M, LP vs E and LT vs E), allowing the
determination of 177 unique proteins with significant differential
expression.
The most striking results were the opposite trends in differential
expression of proteins in the brain during the CHIKV infection in
mice. Prior to the appearance of clinical signs, 80% of the proteins
that were significantly differentially expressed were down-regulat-
ed compared with the mock-infected samples; however, after the
appearance of the clinical signs, irrespective of the type of
symptom, more than 95% of the proteins that were significantly
differentially expressed were up-regulated. The changes in protein
expression profiles occurred rapidly, within 24 hr of the onset of
the acute phase of the disease. The changes in protein expression
profiles were validated by WB analyses for the majority of the
selected proteins. The observed contrasting expression profiles are
consistent with recent proteomic studies using cell lines or mouse
models infected with CHIKV [21,22,23]. In CHIKV-infected
microglial cells harvested before cellular apoptosis, which was
considered to be an early time point, almost all of the proteins that
were significantly differentially expressed were down-regulated
[21]. In another proteomic analysis, Thio and collaborators
reported the down-regulation of 42 out of 50 proteins that were
differentially expressed 24 h after the CHIKV infection of hepatic
WRL-68 cells; this was considered a model system for early
infection time points [22]. Conversely, the analysis of the
proteome changes in the brain of mice infected by CHIKV and
sampled during the phase of acute neurological symptoms revealed
that more than 88% of the proteins were significantly up-regulated
[23]. Consistent with these previously reported alterations in the
protein expression profiles, the present study clearly indicated that
CHIKV infection induces an early dramatic shut-off of host
protein expression, followed by an up-regulation during the onset
of clinical symptoms. These contrasting protein expression
patterns observed using in vitro and in vivo CHIKV infection
models likely reflect the nature of the replication cycle of this virus.
Notably, the majority of proteins that were differentially regulated
(. 62%) were similar in the three comparisons performed (E vs M,
LP vs E and LT vs E), and the level of similarity was as high as 88%
at the late time points (i.e., LP vs LT). Additionally, in the LP vs LT
comparison, the expression levels of the common proteins varied
in the same direction. These alterations in the protein expression
patterns likely reflect the host response in combination with the
hijacking of the host protein repertoire for successful viral
multiplication and might have important consequences on viral
pathogenicity and neurological symptoms.
The in silico analysis of proteins that were differentially expressed
among the three compared groups (i.e., E vs M, LP vs E and LT vs
E) revealed that the main functions and processes altered during
the course of CHIKV infection in the mouse brains were as
follows: i) integrin signaling and cytoskeleton dynamics, ii)
endosome recycling machinery and synapse function, iii) regula-
tion of host gene expression, and iv) modulation of the ubiquitin-
proteasome pathway. Several proteins had roles in multiple
biological functions, indicating the interconnectedness of these
functions. The networks and pathways associated with the
differentially expressed proteins are potential pathophysiological
processes of neurological CHIKV infection and offer possible
biomarkers or therapeutic targets for the diagnosis and prevention
of these severe manifestations, as discussed below.
i) Integrin signaling and cytoskeleton dynamics
Bioinformatic analysis pointed out that several proteins that
were significantly differentially expressed were involved in the
integrin signaling cascade and cytoskeleton dynamics, including
ITGAV, ITGB1, LAMB1, ARPC1B, CORO2B, RAB35, PICK1,
MYPT1, DNM1, and TBB3 (Figure 6). Interestingly, the integrins
ITGAV and ITGB1 were found in almost all of the highlighted
canonical pathways and in network 2 generated by IPA, suggesting
the central role of these membrane proteins. Integrins are
composed of alpha and beta subunits and are known to facilitate
signal transduction and participate in a variety of processes,
including cell growth, blood vessel permeability, tissue repair and
immune response [33]. These membrane proteins also function as
receptors for diverse viruses and act as signal transducers during
virus entry [34]. Although some cell surface proteins are potential
receptors for CHIKV entry into the host cells, the precise
mechanism is still unclear [35,36]. In the present study, the down-
regulation and up-regulation of aV integrin (ITGAV) and b1
integrin (ITGB1) were observed over the time course of the
appearance of clinical signs. The aV/b1 integrin heterodimer is
utilized by various adenovirus serotypes for cell entry [37,38]. In
addition, members of the integrin superfamily serve as entry
receptors for the Ross River alphavirus and the West Nile virus
(WNV) [39,40]. Therefore, it will be interesting to test whether the
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aV/b1 integrins could be involved in CHIKV attachment or entry
into the host cells. In this case, the decrease and subsequent
increase in the level of this membrane receptor could first limit and
then promote virus entry, respectively. The targeting of integrin
receptors is a possible therapeutic strategy against tumor
development [41]. Recently, it was shown that the use of aV/b1
antibodies or antagonists prevented the outgrowth or dissemina-
tion of carcinoma [42]. Therefore, the candidate drugs targeting
aV/b1 integrins could be evaluated for their efficacy in the
protection against CHIKV infection or prevention of severe cases.
Notably, the extracellular matrix component LAMB1 was
found to be differentially expressed, consistent with previous
results using resident brain macrophages infected with CHIKV
[21]; LAMB1 can interact with integrin b1, triggering cytoskeleton
modifications [43]. The integrin signaling cascade includes the
phosphorylation/activation of several protein families, such as the
Rho family of small GTPases [44]. Many viruses can hijack the
Rho GTPase pathway for efficient virus replication and produc-
tion [45]. In the present study, the expression levels of several
proteins connected to the Rho GTPase pathway were found to be
altered (Figure 6), for instance, the Rab GTPase RAB35, a protein
that controls the endocytic recycling pathway [46] and participates
in the maintenance of cellular adhesion by the inhibition of factors
involved in integrin recycling [47]. Disturbance of the equilibrium
between these factors could lead to the rupture of cell adhesion,
leading to blood vessel permeability and facilitating the crossing of
the blood brain barrier by CHIKV.
Figure 3. Classification of proteins significantly differentially regulated following CHIKV infection identified by 2D-DIGE and iTRAQ
analysis. Significantly differentially regulated proteins were classified according to their sub-cellular location (A) and their functional categorization
(B) according to gene ontology. The percentages of proteins associated with each category are indicated in brackets. (C) Venn diagram representing
unique host proteins identified according to experimental group comparisons following CHIKV-infection by combined 2D-DIGE and iTRAQ analyses.
The number of host proteins significantly differentially regulated between early (E) vs mock (M), late paralytic (LP) or late tetanus-like (LT) vs E are
indicated. The number of proteins associated with each category is indicated with corresponding percentage in brackets. (D) Hierarchical clustering
analysis was performed according to the mean ratios calculated between E vs M, LP vs E and LT vs E, as indicated at the top of the graphic. Up- and
down-regulated proteins are shown in red and green, respectively, and proteins with no statistically change in expression level are indicated in black.
The intensity of red or green color corresponds to the degree of regulation as indicated by the color strip at the top of the figure in arbitrary units.
The graphical cluster was generated using the Genesis program [87].
doi:10.1371/journal.pone.0091397.g003
Figure 4. Top-2 most significant protein networks of differentially regulated proteins following CHIKV infection. Ingenuity Pathway
Analysis of the total 177 proteins identified as differentially expressed generated 2 emerging networks with high score and including more than 20
molecules with direct relationships. Network 1 (A,B,C) was associated with Cell Morphology, Tissue Morphology, Infectious disease and Network 2
(D,E,F) with Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Cellular Compromise. Each network was overlaid with the
protein expression fold-change determined in each separate comparison (early (E) vs mock (M) (A, D), late paralytic (LP) vs E (B, E) or late tetanus-like
(LT) vs E (C, F)), to highlight the proteins modified during the time-course of infection. Individual proteins are represented as nodes colored in red and
green corresponding to up- and down-regulated proteins, respectively, while the nodes (proteins) in white have been added by IPA to maximize the
network connectivity. The different shapes of the nodes represent functional classification of the proteins as indicated in the legend.
doi:10.1371/journal.pone.0091397.g004
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The altered expression of other proteins involved in microtubule
filament formation (ARPC1B) [48], brain cytoskeleton rearrange-
ment/motility (CORO2B, MYPT1) [49,50] and synaptic plasticity
(PICK1) [51] highlighted the importance of changes in cellular
cytoskeletal maintenance and molecular trafficking (Figure 6).
Alteration of the coronin protein level (CORO1A) in CHIKV-
infected brains was previously observed [23].
Other cytoskeleton-related proteins such as dynamin (DNM1)
and Tubulin beta-3 chain (TUBB3) were up-regulated only at the
early time point. The role of the cytoskeletal network in CHIKV
endocytosis has been demonstrated using actin- or tubulin-specific
depolymerizing agents, highlighting the importance of intact actin
filaments and microtubules for CHIKV infection [52].
ii) Endosome recycling machinery and synapse function
Similar to the cytoskeletal dynamics-related changes, several
proteins that were differentially expressed during the time course
of CHIKV infection in the brain were related to the endocytic
machinery, including Rabaptin-5 (RABEP1), RAB35, N-ethylma-
leimide–sensitive fusion protein (NSF), GRIP-associated protein 1
(GRIPAP1 or GRASP1), and annexin-A2 (ANXA2); this class of
proteins was mainly down-regulated at the early stage of infection
and then up-regulated at the later time-points (Figure 6). The
identification of the differential expression of the proteins involved
in different steps of endosome trafficking, such as RABEP1,
involved in early endosome fusion [53,54], NSF, in membrane
fusion and transport [53,55], GRIPAP1, in endosome recycling
[56], RAB35, in endosome recycling to the membrane [57,58] and
ANXA2, in different steps from early endocytosis to endosome
recycling [59], suggested the strong perturbation of this pathway
following CHIKV infection. Diverse viruses including CHIKV use
different stages of this endocytic pathway for efficient infection
[52,60,61,62,63,64,65]. Endosome trafficking appears to play a
key role for the CHIKV replication cycle, and the proteins
identified in the present study could represent potential drug
targets for the control of viral spreading. Drugs licensed for human
use targeting the Rab GTPase network are already available [66];
these drugs could be tested against CHIKV infections.
Several differentially expressed proteins identified in the
CHIKV-infected brain samples were associated with neurotrans-
mitter receptor recycling, which is involved in synapse functions
(Figure 6). The c-aminobutyric acid receptor subunit alpha-1
(GABAAR1 or GABRA1), which mediates post-synaptic trans-
mission in the vertebrate CNS, presented an early down-
regulation and late up-regulation with the onset of clinical signs.
The differential expression of GABRA1 is associated with the
modulation of the phosphatase and tensin homolog (PTEN), a
synaptic signaling protein [67] and arrestin-b1 (ARRB1), both of
which activate the PI3K pathway, leading to the regulation of
GABRA1 membrane expression and function [68,69]. ARRB1,
NSF, PICK1 and GRIPAP1 were related to the endocytosis/
recycling process of other neurotransmitter receptors (GPCRs or
AMPARs) [56,70,71,72]. In addition, the synaptic vesicle protein
synaptogyrin (SYNGR3), which is involved in neurotransmission
[73,74], was also found to be differentially expressed in this study.
The alteration of these protein levels in CHIKV-infected brains
indicates a profound impairment of receptor signaling, leading to
synapse dysfunction. The resulting alteration of neurotransmission
may be, in part, associated with severe neurological CHIKV
infection, as observed in patients with HIV encephalitis with
differential expression of the genes encoding the neuronal
molecules involved in synaptic plasticity, including synaptogyrin
[75]. Further studies are needed to precisely determine the balance
between receptor endocytosis, late recycling to the membrane and
degradation and the effect on synaptic plasticity from early to
severe CHIKV infection. GABAAR are targets of several anti-
seizure pharmacological compounds such as benzodiazepines [76].
Table 2. Top-5 networks from IPA of the total 177 proteins differentially expressed identified by 2D-DIGE and iTRAQ labeling
following CHIKV infection, considering the 3 comparisons of early (E) vs mock (M), late paralytic (LP) or late tetanus-like (LT) vs E
samples.
Top Functions Score
Focus
Molecules Molecules in Network
Cell Morphology, Tissue Morphology,
Infectious Disease
55 28 Actin, Alpha Actinin, Alpha catenin, ARL15, ARRB1, CAPZA1, CORO2B, CRMP1, CRMP,
CSRP1, DCTN1, DNM1, DPYSL2, DPYSL3, EIF3H, EIF3K, F Actin, GNPAT, GRIPAP1,
KCNQ2, KIF3A, LANCL1, LRP1B, PPAP2B, RAB35, SDC3, SEPT8, SF3B2, SMPD3,
SORBS1, Spectrin, SPTAN1, SPTBN1, SRRM2, Tubulin
Cell-To-Cell Signaling and Interaction,
Cellular Assembly and Organization,
Cellular Compromise
37 22 Alpha actin, Alpha tubulin, ANXA2, ATPase, Beta Tubulin, Caveolin, Collagen type IV, DLAT,
DYNC1LI1, EPN2, Focal adhesion kinase, GABAR-A, GABRA1, ITGAV, ITGB1, LAMB1, NSF,
p85 (pik3r), Pdgfr, PFDN2, phosphatase, PICK1, PLC gamma, PPME1, PPP1R12A, PPP2CB,
PTEN, PTPRF, RABEP1, Rbx1, Rnf213, SLC9A3R1, TUBB3, UBE2K, Ubiquitin
Post-Translational Modification,
Cancer, Reproductive System Disease
27 17 ACTC1, ANO10, ARMCX2, BRI3BP, EML2, FAM65A, FLAD1, GEMIN4, HEATR5B, LPIN1,
LPIN2, LPPR3, LRRC49, MAP7D2, MPC1, NEK6, NUDT21, OGFR, PENK, PHF5A, PITHD1,
PPAP2A, PPAP2B, PPAP2C, PPP2R2D, PREB, PRTFDC1, RCC1, RIOK2, SF3B1, SUMO4, TRIM23,
TRIP13, TSTA3, UBC
Developmental Disorder, Hereditary
Disorder, Metabolic Disease
25 16 ADO, AGTPBP1, APRT, ARMC1, ATP11A, ATP11B, ATP11C, ATP8A1, CBS, CHMP4A, HPS6,
LMAN2, MB21D2, MCCC1, MCCC2, miR-3974 (miRNAs w/seed AAGGUCA), NYNRIN, PNKP,
PPFIA1, PPFIA4, SLC37A4, SLC9A6, SPRED1, SUPT5H, SYNGR3, TENM2, TENM3, TMEM30A,
TMX1, TTC19, UBC, UGP2, UPF3B, ZFYVE26, ZNF326
Cell Cycle, Connective Tissue
Disorders, Developmental Disorder
25 16 ARHGAP23, ARPC2, ARPC4, ARPC1A, ARPC1B, ARPC5L, ATXN2L, BCL2L13, C11orf58,
C6orf170, CLSTN1, CNTNAP2, CORO1B, HMGB3, KIFC1, MBTPS1, MCM3AP, MINK1, NFS1,
NUP107, NUP205, POF1B, RASGRF2, RBM10, SAR1B, SLC44A1, SLK, TMED7, TMPRSS3, TPR,
U2SURP, UBC, UBXN4, WDR41, ZFR
Molecules from the uploaded dataset are indicated in bold. Fold-change expression values of these molecules in each paired comparison are indicated in Tables 1, S4
and S5.
doi:10.1371/journal.pone.0091397.t002
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The potential beneficial effect of these molecules in neurological
cases of CHIKV infection should be investigated.
Together, these data showed that the endosomal machinery was
affected by CHIKV infection in the brain, which could facilitate
virus entry and spread and potentially cause the dysregulation of
synapse function and neurotransmission (Figure 6).
iii) Regulation of gene expression
Because viral genomes are small with limited protein encoding
ability, viruses require host transcriptional and translational
machineries to complete their replication cycle. Furthermore,
the alphaviruses, including CHIKV, induce the cessation of host
transcription/translation in infected cells [77,78,79]. Here, several
proteins involved in mRNA processing and translation, including
transcription factors (TFAM, PNN), splicing factors (SRRM2,
SF32B2, U2AF1, RMB17, PHF5A,) and translation initiation
factors (EIF3H and EIF3K) were differentially expressed (Figure 6).
Apart from SRRM2 and PNN, all these proteins were down-
regulated and up-regulated at early and late time points (i.e., LT
and LP), respectively. The early down-regulation of proteins
regulating gene expression and/or translation was reported in
previous proteomic studies using CHIKV-infected cells [21,22].
The differential expression of splicing and translation proteins,
including EIF3, has also been detected following infection with
other viruses [26,80].
Altogether, these data supported that CHIKV infection, similar
to infection with other viruses, perturbed the host protein synthesis
machinery at different levels: transcription/translation and mat-
uration, which could explain the down-regulation and up-
Figure 5. Western blot validations of differentially regulated proteins identified by 2D-DIGE and/or iTRAQ analyses. (A) Protein
samples from each group used for proteomic analysis were minimally labeled with cyanine-3 dye. At the top, a representative protein profile of three
biological replicates from brain lysates of mock (M), early (E), late paralytic (LP) and late tetanus-like (LT), separated by 10% SDS-PAGE is shown. WB
with fluorescence-based methods was used to detect an overlaid fluorescent scan of the general protein patterns (Cy3 dye; green) and the specific
immunoreactive proteins (FITC or Cy5 dye; red). To better visualize protein detection signals observed with each specific antibody used,
corresponding cropped WB images are presented in grey levels. (B) The graphs correspond to the mean 6 S.D. of protein quantity measured by
densitometry of the antigenic bands. Densitometry analyses were performed using TotalLab Quant v12.2 software (Nonlinear Dynamics), and data
were normalized to levels of global protein pattern intensity. The values indicated under each graph correspond to fold changes from paired
comparisons. The significance of the differential protein expression are indicated *, p,0.05; **, p,0.01; ***, p,0.001. A.U., arbitrary units. ANXA2:
annexin A2; ARRB1: b-arrestin; GABRA1: c-aminobutyric acid receptor subunit alpha-1; GRASP1: GRIP-associated protein; ITGAV: integrin aV; MYPT1:
myosin phosphatase target subunit 1; N-Ras: N-Ras; RABEP1: rabaptin-5; SYNGR3: synaptogyrin-3.
doi:10.1371/journal.pone.0091397.g005
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regulation of the differentially expressed proteins at the early and
late stages of the infection, respectively (Figure 6). Further studies
on these regulators of gene expression will elucidate their
contribution to CHIKV pathogenesis.
iv) Modulation of the ubiquitin-proteasome pathway
(UPP)
The ubiquitin-proteasome pathway (UPP) is indispensable for a
variety of cellular processes including the control of protein
stability, protein trafficking, the regulation of signal transduction
pathways and antiviral responses [81,82]. Conversely, the
hijacking of the UPP by diverse viruses prevents viral protein
degradation, aiding evasion of the host immune response, and also
enables viral replication, viral particle assembly and egress [83]. In
this study, six UPP-associated proteins were differentially ex-
pressed during the neurological CHIKV infection (i.e., RBX1,
RNF213, RAD23A, GPS1, USP13 and UBXN6) (Figure 6). Ring
box protein-1 (RBX1) and Ring finger protein 213 (RNF213) are
E3 ubiquitin-ligases that function in protein ubiquitination. The
opposing directions of differential expression of the two E3
ubiquitin-ligases before and after the onset of clinical symptoms
indicated the nuanced regulation of these proteins. Because E3
ligases are the components of the ubiquitin cascade that confer
substrate specificity, knowledge of their specific host and/or viral
protein targets might clarify whether the observed E3 ligase
expression patterns are more beneficial for the pathogen or the
host. The alteration of E3 ligase expression was previously
observed in the brain of mice infected with WNV [27], indicating
that the expression of these proteins is particularly perturbed after
viral infection. The nucleotide excision repair protein RAD23A
interacts with the 19S subunit of the 26S proteasome to deliver
poly-ubiquitinated proteins to the proteasome for degradation. Li
and collaborators showed that in HIV-infected macrophage cells,
the HIV-1 viral protein R (Vpr) interacts with the proteasome
through RAD23A to promote host protein degradation [84]. The
decreased expression of the RAD23A protein in macrophages led
to a decrease in HIV replication, indicating the crucial role of
RAD23A in viral multiplication. Li et al. suggested that the
interaction between Vpr, RAD23A and the 26S proteasome could
lead to the degradation of antiviral factors [84]. Finally, two de-
ubiquitinating enzymes (DUBs), ubiquitin carboxyl-terminal hy-
drolase 13 (USP13) and ubiquitin regulatory X domain-containing
protein-6 (UBXN6), were down-regulated and up-regulated,
respectively, before and after the onset of clinical symptoms in
mice infected with CHIKV. This is the first report of the
differential expression of DUBs following an alphavirus infection.
The consequences of the differential expression of the DUBs need
to be explored to clarify their involvement in CHIKV infection.
The large number of proteins from the UPP that are differentially
expressed following CHIKV infection highlights the crucial role of
Figure 6. Diagram summarizing the main interconnected pathways and biological processes altered following CHIKV infection in
mouse brain. Proteins found to be differentially expressed in the study are shown in bold. Related proteins are shown in italics.
doi:10.1371/journal.pone.0091397.g006
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this pathway. Recently, the rapid down-regulation of the UPP
proteins was observed following CHIKV infection in a hepatic cell
line; however, none of the same proteins were detected relative to
this study [22]. Notably, several molecules targeting E3-ligases,
DUBs or the proteasome are candidates for cancer treatment [85],
which highlights novel potential therapeutic strategies targeting
the UPP in CHIKV infection.
Conclusion
The analysis of differentially protein expression during the
time course of CHIKV infection indicated the profound down-
regulation of proteins in the early stage, followed by a rapid up-
regulation after the appearance of clinical symptoms, consistent
with the previously reported dramatic cessation of protein
expression in CHIKV-infected cells. These analyses revealed
that the differentially expressed proteins were involved in several
biological processes including i) cell signaling via integrins, which
is related to cytoskeletal dynamics, ii) endocytosis and receptor
recycling, which are associated with virus circulation and
synapse function, iii) the host translational machinery, which
reflects the regulation of protein expression, and iv) modulation
of the ubiquitin-proteasome pathway. By revealing the protein
expression profiles correlated with the onset of clinical symp-
toms, this study paves the way for further studies on the
evaluation of potential disease markers and the development of
new therapeutic targets to prevent the CHIKV neurological
infection.
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Figure S1 2D-DIGE analysis (pH 4–7) of mock-(M) and
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